ARS Pharma (SPRY) Gains China Approval for Neffy, Roth Reiterates Buy Rating

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) is one of the 12 Stocks that Will Bounce Back According to Wall Street Analysts. On January 2, Roth MKM reiterated its Buy rating on ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) with a price target of $30 on the stock. In other news, on December 29, ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) reported that China’s National Medical Products Administration (NMPA) has approved neffy 2 mg, an epinephrine nasal spray, for the emergency treatment of Type 1 allergic reactions, anap ...